Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Recognizes human PAR-4. No significant cross-reactivity or interference was observed.
LS-F12261 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the Quantitative detection of Human F2RL3 / PAR4 in samples of Plasma and Serum. It is based upon a Sandwich assay principle and can be used to detect levels of F2RL3 / PAR4 as low as 0.78 nanograms per millilter.
96-Well Strip Plate
Colorimetric - 450nm (TMB)
0.78 - 50 ng/ml
Intra-Assay: CV<10% / Inter-Assay: CV<12%
Due to their limited shelf life, LSBio ELISA kits are not typically stocked as finished goods. Upon receipt of an order each kit is assembled and tested to ensure that it meets specifications before shipping. Minor changes may occur to the Range, Sensitivity, and Precision. In the event of a significant change the order would be confirmed with the customer before shipping ELISA kit lot numbers reflect the date of final assembly and testing for each specific kit rather than a bulk manufactured lot. All kits are tested to confirm that they fall within their defined Inter- and Intra- assay coefficient of variation.
Proteinase-Activated Receptor 4 (PAR4) is a member of the Proteinase-Activated Receptor subfamily. Along with other protease-activated receptors, PAR4 mediates the effects of the enzyme, thrombin which include activation of platelets, leukocytes, endothelial cells, and mesenchymal cells at sites of vascular injury. These cellular responses are triggered through proteolytic activation of the receptors by thrombin.